drugset / Trial / NCT07525219

Suzetrigine Frame Trial Comparing Suzetrigine and Acetaminophen

NCT07525219

Phase 3 Not yet recruiting 80 enrolled Wake Forest University Health Sciences
RandomizedParallel-groupDouble-blindSupportive care

Summary

Local anesthetic infiltration is a primary source of acute pain during stereotactic procedures.

Timeline

Start
2026-07
Primary completion
2027-07
Completion
2027-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Acetaminophen Small molecule 1000 mg
Subject Suzetrigine Small molecule 100 mg

Indications

No indication recorded.